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  20 
Background: There are many uncertainties concerning variations in benzo[a]pyrene (B[a]P) 21 
soil guidelines protecting human health based on carcinogenic data obtained in animal studies. 22 
Although swine is recognised as being much more representative of the human child in terms 23 
of body size, gut physiology and genetic profile the rat/mice model is commonly used in 24 
practice.  25 
Objectives: We compare B[a]P bioavailability using a rat model to that estimated in a swine 26 
model, to investigate the correlation between these two animal models. This may help reduce 27 
uncertainty in applying bioavailability to human health risk assessment.   28 
Methods: Twelve spiked soil samples and a spiked silica sand (reference material) were 29 
dosed to rats in parallel with a swine study. B[a]P bioavailability was estimated by the area 30 
under the plasma B[a]P concentration-time curve (AUC) and faecal excretion as well in the 31 
rats. Direct comparison between the two animal models was made for: firstly, relative 32 
bioavailability (RB) using AUC assay; and secondly, the two assays in the rat model.  33 
Results: Both AUC and faecal excretion assays showed linear dose-response for the reference 34 
material. However, absolute bioavailability was significantly higher when using faecal 35 
excretion assay (p < 0.001). In aged soils faecal excretion estimated based on solvent 36 
extraction was not accurate due to the form of non-extractable fraction through ageing. A 37 
significant correlation existed between the two models using RB for soil samples (RBrat = 38 
0.26RBswine + 17.3, R2 = 0.70, p < 0.001), despite the regression slope coefficient revealing 39 
that the rat model would underestimate RB by about one quarter compared to using swine.  40 
Conclusions: In the comparison employed in this study, an interspecies difference of four in 41 
RB using AUC assay was identified between the rat and swine models regarding 42 
pharmacokinetic differences, which supported the body weight scaling method recommended 43 
by US EPA. Future research should focus on the carcinogenic competency 44 
(pharmacodynamics) used in experiment animals and humans.  45 
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Introduction  47 
Benzo[a]pyrene (B[a]P), a high molecular weight polycyclic aromatic hydrocarbon (PAH), is 48 
known as a probable human carcinogen based on increased occurrence of lung, dermal and 49 
gastro-intestinal tumours appearing in laboratory animals exposed to B[a]P (U.S. EPA 1994). 50 
Along with other PAHs, B[a]P mainly forms as a result of incomplete combustion of organic 51 
substances with both natural and anthropogenic origins (FAO/WHO 1991). It commonly 52 
occurs at current and disused industrial sites, such as coal gasification and coke production 53 
plants, aluminium, iron and steel foundries, and creosote and asphalt production works 54 
(Zhang et al. 2009). Although commonly found as PAH mixtures, B[a]P has often been used 55 
to indicate the risk of PAHs (Bostrom et al. 2002; CCME 2010; FAO/WHO 2006; HPA 2010; 56 
MfE 2011; Schneider et al. 2002).  57 
 58 
Given the lack of human epidemiological studies, the current soil guidelines for B[a]P and 59 
PAHs in Australia and many other countries are based on carcinogenicity in rodent (Brune et 60 
al. 1981; Culp et al. 1998; Neal and Rigdon 1967). Typically, a benchmark dose (BMD) that 61 
gives rise to a 10% response (BMD10) derived from fitting of dose-response data is used as a 62 
point of departure (PoD). For B[a]P, a lower confidence limit of BMD10 (BMDL10) of 0.1 63 
mg/kg body weight per day was used to calculate the risk of PAHs in food (MfE 2011). From 64 
this critical toxicological value in animal studies large safety factors were applied to address 65 
uncertainties in extrapolating them to humans (Safety 2014). More detailed information about 66 
the uncertainties associated with extrapolation has been documented in Dong et al. (2015). 67 
Briefly, a margin of exposure (MoE) approach of 1/10,000 was applied in Europe (HPA 68 
2010), in which a modifying factor of 10 was employed to account for the interspecies 69 
differences between mice and humans. The US EPA used the same default factor accounting 70 
for the interspecies differences but also recommends using a body weight (bw) scaling factor 71 
and a rounded uncertainty factor of 3 when considering the results of different animal models 72 
(U.S.EPA 2011). An interspecies uncertainty factor of 5 was adopted in a study developing 73 
soil guideline in Australia, where a guideline value of 5 mg/kg for B[a]P was derived 74 
(Fitzgerald et al. 2004). This value is very close to the current national soil guideline (4 mg/kg) 75 
for residential land use in Australia (NEPC 2013). 76 
 77 
Besides the uncertainty over interspecies differences, exposure from ingestion of 78 
contaminated soil does not delineate between the fraction that subsequently absorbs 79 
(bioavailable fraction) and the total concentration. Such an approach is likely to result in 80 
overestimation of risk and as a consequence remediation of sites that could potentially be safe. 81 
In the latest National Environmental Protection Measure of Australia, using site-specific oral 82 
bioavailability data of contaminants has been encouraged when available (NEPC 2013). 83 
Bioavailability is defined as an internal estimation of the actual uptake or absorption of 84 
contaminants that enters the body (internal dose), and therefore provides a better estimation of 85 
the risk. Significantly reduced bioavailability of some PAH(s) in soil has been reported using 86 
animal models including goat and rat in comparison to dose in solution (Goon et al. 1990; 87 
Goon et al. 1991) or oil feed (Ounnas et al. 2009; Pu et al. 2004; Van Schooten et al. 1997). 88 
However, there is considerable uncertainty regarding the utilisation of oil as a reference 89 
material in these studies given its lack of relevance to environmental exposure, and therefore 90 
the implication of these results being used in modifying current soil guidelines. Also, 91 
compared to rodents, swine are preferred for human health risk assessment as they share many 92 
similar traits to humans, such as body weight, anatomy, genetics and physiology (Ng et al. 93 
2013; Walters and Prather 2012). However, conduct swine study is much more expensive 94 
compared to using rat. As a consequence, to date only a handful of animal studies have used 95 
swine to estimate PAH bioavailability in soils (Duan et al. 2014; James et al. 2011; James et 96 
al. 2016; Peters et al. 2015).  97 
 98 
The limited number of swine studies and the lack of data illustrating interspecies extrapolation 99 
prompted us to carry out a comparative study using both rats and swine. The swine study 100 
result was published earlier with the focus on the effects of soil properties and ageing on 101 
B[a]P bioavailability (Duan et al. 2014). In this paper, we present a parallel rat study, in 102 
which B[a]P bioavailability was calculated using two different assays: plasma versus faeces. 103 
The major objectives of this study are: 1) to investigate if consistent bioavailability results 104 
could be found using the rat model instead of the more expensive swine model; 2) to compare 105 
the bioavailability results obtained from the two assays in the rat model. Finally, we discuss 106 
implications for human health risk assessment of bioavailability data from the rat and swine 107 
models.  108 
Materials and methods 109 
Soils  110 
Eight soils varying in soil properties including organic matter (TOC: 0.72 ~ 7.5%; DOC: 8.5 111 
~ 108.4 mg/L), clay content (5.6% ~ 30.9%), pH, EC, CEC (and clay mineralogy), and 112 
texture, etc., were employed in this study. Detailed soil properties are presented in Table 1.  113 
Insert Table 1 114 
The soils were spiked at a B[a]P concentration of 50 mg/kg on a dry weight basis as described 115 
in the swine study. Briefly, following pre-treatment of soils, an appropriate portion of the 116 
sample was spiked with 1% (v/w) B[a]P stock solution (5000 mg/L) prepared in a mix-solvent 117 
(toluene : acetone = 1:1, v/v). Additional 1% (v/w) acetone was used to rinse the glass storage 118 
vial three times to ensure complete transfer of the mass. Spiked samples were left in a fume 119 
hood for 24 h to allow the solvent to evaporate. Following this, each sample was 120 
homogenised again before being stored for ageing. Homogeneity of the spiked samples and 121 
the spike recovery were carefully examined by checking the concentrations of B[a]P in 122 
subsamples.  123 
An exhaustive solvent extraction method, modified from US EPA method 3550, using a 124 
mixed solvent including a water-miscible solvent-acetone and a water-immiscible solvent-125 
dichloromethane (DCM/Ace) at 1:1 ratio (v/v) was used to measure the sample 126 
concentrations. The extraction was facilitated by sonication in a water basin (40 kHz, 15 min 127 
twice) and was repeated three times for each sample. Specifically, 1.5 g soil or sand was 128 
mixed with 3 g anhydrous sodium sulphate using a stainless spatula and extracted three times 129 
with 10 mL of the mixed solvent extractant each time. The solvent extract was separated 130 
following centrifugation. Samples were vortexed in between extraction to maximum mixing. 131 
The combined extract was evaporated under gentle nitrogen gas flow, following which 5 mL 132 
acetonitrile was added to uptake the sample and about 2 mL aliquant was filtered through a 133 
0.45 μm PTFE syringe and stored in an amber HPLC vial for analysis. Spike recovery in sand 134 
was > 99% (99.7 ± 0.5%, n = 5) and in soil ranged from 85.2 ± 0.3% to 92.6 ± 4.8% (n = 3) 135 
using four contrasting soil samples (Duan et al. 2014).  136 
After spiking, the soils were stored in glass jars and deionised water added to bring the 137 
moisture content to 60% of the specific water-holding capacity for each sample. Following 138 
this, samples were kept in darkness at room temperature (22 ± 3 ºC) over the ageing period 139 
(90 days). 140 
The experiment design 141 
The aged soil samples were air-dried overnight and pulverised before being dosed to rats and 142 
swine at the same time. A single dose was given to each group of animals in triplicate. In total 143 
there were 12 sets of data used in the rat and swine model comparison, including eight soil 144 
samples after 90 days of ageing (D90) and four soil samples selected due to contrasting soil 145 
properties dosed at 50 days of ageing (D50) as well to test the effect of ageing.  146 
Before testing bioavailability in soils, we performed a dose-response study using silica sand 147 
(Sigma-Aldrich Pty Ltd, Sydney, Australia) as a reference material in both the rat and swine 148 
models, with the silica sand spiked as described for soils.  149 
Rat bioavailability assay 150 
This study was approved by the Animal Ethics Committee of the South Australian Health and 151 
Medical Research Institute (SAHMRI) (AEC approval number 47/12). Animal care and 152 
surgical procedures complied with both the Standard Operating Procedures of the Veterinary 153 
Services Division, Institute of Medical and Veterinary Science and the Australian code of 154 
practice for the care and use of animals for scientific purposes (NHMRC 2013). Prior to being 155 
used in experiment, Male Sprague-Dawley rats (300 ± 20 g, from Animal Resource Centre, 156 
WA, Australia) were acclimatised for about one week to reach 350 ± 50 g body weight (bw). 157 
They were housed in plastic boxes in groups of two in a room at 22 ± 3ºC, 50% humidity, and 158 
a 12/12 h light/dark cycle, with standard rodent lab feed (Specialty Feeds, Glen Forrest, 159 
Australia) and water provided ad libitum. Prior to treatment the animals were housed 160 
individually and fasted for 16 h. Constrain to food access was maintained until 2 h post 161 
dosing.  162 
 163 
In the experiment, soil/sand sample was suspended in a food thickener paste (at 8%, Karicare 164 
food thickener, mainly containing maltodextrin, starch from maize, carob, bean gum) and 165 
administered as slurry by gavage using a 14G animal feeding needle (Able Scientific, 166 
Australia). The dose rate was 2 g/kg bw at 0.25 g soil/mL and 8 mL/kg bw. Equivalent dose 167 
(100 µg/kg bw) of B[a]P was administered by intravenous (IV) injection through the tail vein 168 
at an injection volume of 2 mL/kg bw in an ethanol : fresh clean rat plasma at a ratio of 1: 4 169 
(v/v) modified from previous studies (Pu et al. 2004; Weyand and Bevan 1986).  170 
 171 
The dose remaining in the syringe and gavage needle was rinsed three times with water, 172 
ethanol and water again into the dose storage tube and estimated by determining the mass dry 173 
weight using a filter paper. On average, 8.9 ± 1.7% (n = 18) of the dose was un-dosed for 174 
sand and for soils this ranged from 7.0 ± 0.2% to 12.5 ± 1.8% (n = 3), on average at 8.4 ± 175 
1.4%. These adjustments were made in rats in order to compare BA with that in swine where 176 
dosing was complete. 177 
 178 
Serial blood samples (~0.25 mL) were collected from tail veins in heparinised tubes at 0.25, 179 
0.5, 1, 1.5, 2, 4, 6, 8 and 24 h following oral administration of the spiked soil or sand. For IV 180 
dosing, additional samples at 5 min and 10 min were collected. An indwelling IV catheter was 181 
used for the first 4 h of blood collection while the remaining time points of samples were 182 
collected by tail vein bleeding using needle sticks. Background samples were taken from 183 
control rats in the same batch. Plasma was separated immediately by centrifugation at 1037 g 184 
for 15 min and about 0.12 mL aliquot of sample was taken and stored in an amber glass vial 185 
(4 mL) with PTFE-lined cap at -20°C until extraction.  186 
 187 
Extraction of B[a]P from plasma was carried out as described in the swine study (Duan et al. 188 
2014) with a slight modification, wherein 1.5 mL hexane instead of three times the sample 189 
volume was added to each vial and subjected to sonication (40 kHz, 5 mins) twice. Spike 190 
recovery in clean plasma at three concentrations (0.25, 1.25 and 6.25 µg/L) indicated that 191 
average spike recovery ranged from 84.5% to 91.3% with a standard deviation of < 10%. 192 
 193 
Rat faeces samples were collected for each individual in the first 12 h post-oral dosing or IV 194 
injection and then every 24 h until after 72 h. Before extraction faeces samples were stored at 195 
-20°C. A preliminary study showed after 72 h post-dosing further excretion was < 5% for 196 
both soil and sand (Supplemental Material Figure S-1). All rats were sacrificed by cervical 197 
dislocation by the end of the 72 h sampling period.  198 
 199 
Faecal excretion of B[a]P was estimated by the DCM/Ace extraction method used for soil 200 
extraction. The only difference was homogenisation with anhydrous sodium sulphate (about 201 
three times the volume of the faeces) was carried out in a blender after thawing the faeces 202 
from -20˚C to room temperature.  203 
 204 
In total, 18 rats were used for the dose-responses relationship of B[a]P in the reference 205 
material (silica sand coated with B[a]P). Initially, eight rats in four groups of two were given 206 
doses at 20 μg/kg bw, 40 μg/kg bw, 60 μg/kg bw and 100 μg/kg bw in sand. This was 207 
repeated at the end of the study, with two each at the two lower doses and three each at the 208 
higher doses subjected to larger variability. One group of rats (n = 3) was used for the IV dose 209 
to calculate the absolute bioavailability. Twelve groups of rats (n = 3) were used to test soil 210 
samples aged for different times.  211 
 212 
Quantification of B[a]P was carried out using an Agilent 1100 Series HPLC system coupled 213 
with a diode array detector (HPLC-DAD) at a wavelength of 267 nm for soil and faeces 214 
samples, and a fluorescence detector (HPLC-FLD), with an excitation wave length at 297 nm 215 
and emission wavelength at 405 nm, for the plasma samples. An Eclipse PAH reverse-phase 216 
C18 column (1.8 μm particle size, 4.6 μm inner diameter and 50 mm length) coupled with an 217 
XDB-C18 guard column was used for analysis. The column was maintained at 25 °C on both 218 
sides using a column heater. Isocratic elution was performed at a flow rate of 1.0 mL/min 219 
using the mobile phase of acetonitrile: water = 90:10. Each sample run time was 5 min with a 220 
1 min post run before injecting the next sample. Needles were rinsed after each sample. The 221 
retention time for B[a]P was 3.6 min. 222 
Bioavailability of B[a]P 223 
Two types of bioavailability measurements are frequently used in pollutant biota 224 
investigations and risk assessment studies; namely, absolute bioavailability (AB) and relative 225 
bioavailability (RB). AB is defined as the fraction of a dosed amount reaching the systemic 226 
circulation after oral ingestion, while RB is the comparative bioavailability of a specific 227 
chemical for different exposure media given by the same route (Ng et al. 2013). Most 228 
frequently, the time course absorption by the area under the plasma concentration-time curve 229 
(AUC) is used to estimate bioavailability. AB is typically calculated by the AUC of a dose 230 
from oral ingestion compared with that from an IV injection (Equation 1), while the RB of a 231 
chemical is compared in the environmental material (e.g. soil) to a standard reference material. 232 
In this study, silica sand served as the reference material and RB was calculated using 233 
Equation 2:   234 
𝑨𝑨𝑨𝑨 = 𝑨𝑨𝑨𝑨𝑨𝑨𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐 𝒅𝒅𝒐𝒐𝒅𝒅𝒅𝒅𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐⁄
𝑨𝑨𝑨𝑨𝑨𝑨𝑰𝑰𝑰𝑰 𝒅𝒅𝒐𝒐𝒅𝒅𝒅𝒅𝑰𝑰𝑰𝑰⁄
        Equation 1 235 
𝑹𝑹𝑨𝑨 = 𝑨𝑨𝑨𝑨𝑨𝑨𝒅𝒅𝒐𝒐𝒔𝒔𝒐𝒐 𝒅𝒅𝒐𝒐𝒅𝒅𝒅𝒅𝒅𝒅𝒐𝒐𝒔𝒔𝒐𝒐⁄
𝑨𝑨𝑨𝑨𝑨𝑨𝒅𝒅𝒐𝒐𝒔𝒔𝒅𝒅 𝒅𝒅𝒐𝒐𝒅𝒅𝒅𝒅𝒅𝒅𝒐𝒐𝒔𝒔𝒅𝒅⁄
        Equation 2 236 
 237 
AUC for IV injection (AUCIV) was estimated by a one compartment exponential model: 238 
𝐶𝐶𝑡𝑡 = 𝑏𝑏 + 𝐶𝐶0 × 𝑒𝑒−𝑘𝑘𝑡𝑡 
Where Ct is the concentration of B[a]P in the plasma at time t, C0 is the concentration of 239 
B[a]P in the plasma immediately following IV administration (t = 0), b is the background 240 
concentration, and k is the first-order elimination rate constant. AUC equals the integration of 241 
𝐶𝐶0  × 𝑒𝑒−𝑘𝑘𝑡𝑡, which is C0/k. 242 
 243 
AUC for oral doses (AUCsand and AUCsoil) was estimated by a mathematical model based on 244 
gamma distribution (g(t;α,β) = 1) previously described in (Duan et al. 2014):  245 
𝐶𝐶𝑡𝑡 = 𝑏𝑏 + 𝑎𝑎 × 𝑔𝑔(t,α, β) 
Where Ct is the concentration of B[a]P in the plasma at time t, b is background concentration 246 
and AUC equals a as integration of g(t;α,β) = 1.  247 
Integration of AUC terminates when Ct fell to ± 10 % of the back ground concentration (b).  248 
 249 
Bioavailability was also calculated based on faecal excretion (BA) as shown in Equation 3, 250 
given this portion was not bioavailable (Juhasz et al. 2014).  251 
𝑨𝑨𝑨𝑨 = 𝒅𝒅𝒐𝒐𝒅𝒅𝒅𝒅𝒅𝒅 𝒐𝒐𝒂𝒂𝒐𝒐𝒂𝒂𝒔𝒔𝒂𝒂−𝒅𝒅𝒆𝒆𝒆𝒆𝒐𝒐𝒅𝒅𝒂𝒂𝒅𝒅𝒅𝒅 𝒐𝒐𝒂𝒂𝒐𝒐𝒂𝒂𝒔𝒔𝒂𝒂
𝒅𝒅𝒐𝒐𝒅𝒅𝒅𝒅𝒅𝒅 𝒐𝒐𝒂𝒂𝒐𝒐𝒂𝒂𝒔𝒔𝒂𝒂        Equation 3 252 
 253 
In this study the dosed amount was 100 µg B[a]P/kg bw for all soils and the faecal excretion 254 
of B[a]P was the amount of B[a]P in faeces estimated by DCM/Ace extraction. 255 
 256 
The bioavailability between the two animal models was compared using the relative 257 
bioavailability (Equation 2). As an absolute value, BA calculated from rat faecal excretion 258 
(Equation 3) was compared with AB calculated from AUC. 259 
 260 
Implications of RB in soil guideline derivation 261 
RB could be used to adjust exposure of soil-borne contaminants. The cancer risk (CR) as 262 
shown in Equation 4 is associated with a maximum daily intake (DI) or could be referred to as 263 
a RfD and the Cancer Slope Factor (CSF) for the contaminant(s) (U.S. EPA 2007):  264 
𝐶𝐶𝐶𝐶 = 𝐷𝐷𝐷𝐷 × 𝐶𝐶𝐶𝐶𝐶𝐶       Equation 4 265 
Both the RfD and CSF were derived from critical toxicity study based on animal studies. RB 266 
as a measure of internal dose compared to the reference material can be used to adjust RfD. 267 
Therefore, a modified soil guideline value (S) could be estimated as follows: 268 
𝑺𝑺 = 𝑫𝑫𝑰𝑰 × 𝝎𝝎 ×𝒃𝒃𝒃𝒃
𝒅𝒅𝒐𝒐𝒔𝒔𝒐𝒐𝒅𝒅 𝒅𝒅𝒐𝒐𝒔𝒔𝒐𝒐 𝒆𝒆𝒐𝒐𝒔𝒔𝒅𝒅𝒂𝒂𝒂𝒂𝒄𝒄𝒂𝒂𝒔𝒔𝒐𝒐𝒔𝒔 ×𝑹𝑹𝑨𝑨        Equation 5 269 
In which ω is allocation from soil contributing to all pathways and bw is body weight. It 270 
should be noted that for different animals, the CSF may differ depending on the dose-effect 271 
responses. For PAHs, however, a lack of interspecies studies means that this is not well 272 
understood. 273 
Results  274 
Dose-response for reference material using different bioassays in the rat model 275 
Time-course B[a]P plasma concentration profile of IV and oral doses in sand 276 
Figure 1 illustrates the plasma B[a]P concentration-time profile following IV and oral dosing. 277 
After IV injection the plasma B[a]P concentration indicated an exponential decline over time, 278 
decreasing rapidly within two hours to < 2 µg/L followed by a slow decrease and reaching a 279 
background of 0.09 ± 0.01 µg/L after 6 h (Figure 1a). Following oral dosing with sand, the 280 
plasma B[a]P concentration revealed a biphasic process including an initially rapid increase, 281 
reaching a maximum concentration within 1 h, then rapidly decreasing within 2 h, finally 282 
reaching a range ± 10% of the background concentration after 6 h (Figure 1b).  283 
 284 
Insert Figure 1  285 
 286 
Faecal excretion of B[a]P following IV injection and oral doses in sand 287 
 A small portion (0.2 ± 0.1%) of the dose was found in faeces following IV injection (Table 2). 288 
The negligible amount of B[a]P excreted in faeces followed by IV dose suggests that partition 289 
from blood to organ and excretion through bile was negligible at the study dosage of 100 290 
μg/kg bw. This confirms that the excreted fraction of B[a]P following oral dosing in the 291 
present study did not go through hepatic circulation, which infers that this fraction is not 292 
bioavailable. As shown in Table 1, a significant amount (14.7 ± 4.8%) of the dosed B[a]P was 293 
excreted in faeces following oral dosing with sand at the dose rate ranging from 20 µg/kg bw 294 
to 100 µg/kg bw.  295 
 296 
Insert Table 2 297 
 298 
AUC of B[a]P following IV injection and oral doses in sand 299 
The AUC (responses in the rat plasma) was found to increase linearly with the B[a]P dosage 300 
in sand, with AUC = 0.033 dose − 0.50; R2 = 0.98, p < 0.001 (Table 2). AB was consistent 301 
over the dose range between 20 µg/kg bw to 100 µg/kg bw, averaged at 15.1 ± 5.1%. 302 
Similarly, response in faecal excretion of B[a]P was consistent over the dose range, averaged 303 
at 14.7 ± 4.8%. As only a small portion (0.2 ± 0.1%) of the IV dose was detected in faeces at 304 
the dosage of 100 µg/kg bw, BA of B[a]P in sand would be 85.3% on average. This value is 305 
significantly (~ 6 times) higher than AB calculated using AUC (p < 0.001), suggesting 306 
contrasting results would be derived when using different assays in the animal study. 307 
 308 
Bioavailability of B[a]P in soils- rat compared to swine 309 
Table 2 summarises the bioavailability results using the rat model, including: the relative 310 
bioavailability estimated by rat (RBrat); the bioavailability (BA) calculated by the rat faecal 311 
excretion; the relative bioavailability of B[a]P in swine (RBswine); and B[a]P extractability 312 
estimated by two solvent extraction methods using DCM/Ace and BuOH, which showed 313 
significant correlation with RBswine.  314 
 315 
Insert Table 2 316 
 317 
It is apparent that extractability of B[a]P in soils after ageing decreased dramatically and 318 
ranged from 12.2 % to 62.2 % for DCM/Ace extraction and 9.7 % to 58.1 % for BuOH 319 
extraction, respectively. Faecal excretion of B[a]P following oral dosing of soils was 320 
generally low, which resulted in high BA for all soils (> 88 %). Both RBrat and RBswine were 321 
< 100%, with RBrat significantly lower than RBswine (p < 0.001). 322 
 323 
The rat faecal excretion assay 324 
Faecal excretion of B[a]P following oral dosing of all aged soils (from 0.7 ~ 10.6 %) was 325 
even lower than B[a]P excreted following oral dosing of sand (averaged at 14.7 ± 4.8%, Table 326 
1). This suggests that the direct calculation of BA using equation 3 would result in higher 327 
absorption from aged soils than from sand. This is mainly due to the formation of a non-328 
extractable fraction during ageing, which is evidenced by the decrease in extractability after 329 
ageing (DCM/Ace). In fact, a parallel study using 14C-B[a]P in four contrasting soils showed 330 
significant decrease in B[a]P extractability over a 160-day period using the exhaustive 331 
DCM/Ace extraction method (extractability < 50 %). However, a complete sample oxidation 332 
method indicated more than 77% 14C-radioactivity was still present in the soils (Duan et al. 333 
2015).  334 
Our results indicate that bioavailability (BA) using the faecal excretion assay significantly 335 
overestimates the B[a]P bioavailability (RBrat) using AUC.  336 
The AUC assay  337 
Comparison of RBrat and RBswine showed a strongly significant correlation between the two 338 
animal models (RBrat = 0.26 RBswine + 17.3, n = 12, R² = 0.70, p < 0.001, Figure 2), despite 339 
the large variance among the individuals within each group. 340 
 341 
Insert Figure 2 342 
 343 
The effects of ageing on the correlation of RB between the two animal models was observed 344 
by estimating the correlations (R2) of four contrasting soils at D50 and D90. The correlations 345 
(R2) between RBrat and RBswine decreased dramatically after ageing, dropping from 0.95 at 346 
D50 to 0.62 at D90, respectively (Figure 3). Additionally the slope coefficient of the 347 
correlation decreased slightly after longer ageing time, from 0.40 at D50 to 0.26 at D90, 348 
suggesting that the decrease in RB over ageing was more dramatic in the swine model 349 
compared to that in the rat model. In other words, the swine model is more sensitive to the 350 
change in RB in regard to ageing. It is also worth noting that the effect of ageing on RB was 351 
not significant in rats while at least for one highly clayey soil, BDA, in swine the ageing 352 
effect was significant (Table 2).  353 
 354 
Similar to that in the swine model, the influence of simple soil properties was not significant 355 
in RBrat (Supplemental Material, Figure S-2). Nevertheless, the strong significant 356 
relationships between the two complex soil properties identified in the swine study and 357 
RBswine – namely: 1) fine particle associated organic carbon (FPAC) defined as (Silt + 358 
Clay)/TOC; and 2) proportion of < 6 nm pore size with two outlier soils excluded – was found 359 
significant only for one (FPAC) in rats (Supplemental Material, Figure S-3). Also, significant 360 
correlation between B[a]P extractability using DCM/Ace and BuOH and RBswine was not 361 
found for rats (Supplemental Material, Figure S-4). This is mainly due to the lower RB in the 362 
rat model which consequently reduced the difference amongst samples. However, it is 363 
difficult to further improve the accuracy of RB/AUC in rat as it was limited by the small 364 
volume of blood sample that could be drawn from each individual over the required 365 
sampling period. 366 
Discussion 367 
During the last ten years there has been a significant shift towards using chemical 368 
bioavailability in contaminated soils to estimate the risks posed to human health. A tiered 369 
approach was used. Where total concentration is exceeded, conventional extraction (in vitro) 370 
methods mimicking bioavailability processes may be applied to modify the guideline value. 371 
However, the challenge has been to validate these methods against an in vivo animal model 372 
where rodents have been frequently used. This is particularly the case where inter-species 373 
extrapolation to human/large safety factor for relevant uncertainties is applied to protect 374 
human daily exposure. Human and rodent are quite different in terms of body size, 375 
gut physiology (anatomy) and genetic profile which potentially influences the metabolic rate 376 
relevant to certain enzyme activities. Swine has been recognised as a better model for human 377 
for the same reason mentioned above. Comparison of bioavailability data from the rodent 378 
model and swine model is likely to reduce any uncertainty in the interspecies extrapolation to 379 
human. 380 
 381 
Bioavailability of an ingested compound has been described as consisting of three processes 382 
(Oomen et al. 2006): 1) release from the dose matrix; 2) transport across the intestinal 383 
epithelium; and 3) reaching systemic circulation without being metabolised as shown in 384 
Equation 4. 385 
𝑭𝑭 = 𝑭𝑭𝒃𝒃  ×  𝑭𝑭𝒐𝒐 × 𝑭𝑭𝒉𝒉        Equation 6   386 
where F is the bioavailable fraction of the oral dose; Fb is the fraction of an external dose that 387 
could be released from soil (referred to as bioaccessibility); Fa is the fraction of Fb that could 388 
be transported across the intestinal epithelium; and Fh is the unmetabolised fraction of Fa that 389 
finally reaches systemic circulation.  390 
 391 
Several bioassays have been used in bioavailability studies, and besides blood/plasma 392 
concentration and excretion in faeces, the most frequently used bioassay was excretion of 393 
metabolites in urine. However, due to the large variability in metabolism rate among 394 
individuals as well as the unstable nature of PAH metabolites, an accurate dose-responses 395 
relationship which can be used for comparison of bioavailability based on PAH metabolites 396 
has not yet been established, especially at low doses relevant to daily exposure. For long-term 397 
studies tissue concentration may be used. However, not many such experiments have been 398 
carried out for organic contaminants.  399 
In the present study, the plasma B[a]P concentration-time profile was based on the parental 400 
compound (unmetabolised), and the interspecies comparison between rat and swine models 401 
was made using a relative bioavailability data compared to the same reference material. The 402 
time-course plasma B[a]P concentration observed in our study is most similar to a previous 403 
rat study ((Foth et al. 1988) where the published data was reviewed and figure was redrawn in 404 
Crowell et al. (2011) and similar low doses of B[a]P were dosed in peanut oil. However, in 405 
another rat study where a higher dose at 100 mg/kg bw was given, two peaks in the blood 406 
concentration occurred, the first peak at around 2 h being much smaller than the second peak 407 
at around 8 h post-dosing. It was suggested that the second peak relates to hepatic circulation 408 
through bile excretion at high doses. This highlighted the importance of measuring 409 
bioavailability at an environmentally relevant concentration and thus different studies’ results 410 
may not be appropriate, depending on the dose range used especially if the dose-responses 411 
curve was significantly nonlinear. In the dose range (20 ~ 100 μg B[a]P/kg bw) the effect of 412 
hepatic circulation was not obvious (no clear second peak) and the dose-response (AUC) was 413 
almost linear (Figure 4). A linear dose-response correlation was found in the swine study at a 414 
similar dose range as well (Figure 4).  415 
 416 
Insert Figure 4 417 
It is notable that the ratio of AUC in rat was approximately 4 times higher than that in swine 418 
for sand over the dosing range (Figure 4). Meanwhile the correlation between RBrat and 419 
RBswine (Figure 2) showed RBrat is about a quarter of RB swine. The plasma B[a]P profile in rats 420 
is similar to that observed in the swine model despite the actual concentration being much 421 
lower in swine and the peaking concentration occurring slightly earlier in rats, at 0.80 ± 0.29 h 422 
in rat and at 0.99 ± 0.15 h in swine, respectively. The rapid absorption and removal of B[a]P 423 
in plasma is consistent with the highly lipophilic nature of B[a]P (log Kow ~ 6.1) and the 424 
rapid biotransformation. A peaking concentration of B[a]P in blood (serum) at 2 h post-dosing 425 
was observed in another swine study using PAH contaminated soils (James et al. 2011). The 426 
slight difference may be due to the swine being fed a small serving (5g) of dough, instead of 427 
the full meal provided in our swine study (Duan et al. 2014). In another swine study where 428 
14C labelled B[a]P was dosed in milk to pigs and total radioactivity in blood was measured 429 
over time, a peaking radioactivity at 6 h following oral dosing was observed (Laurent et al. 430 
2001). Employing a radiolabelled compound is a good approach for estimating total 431 
absorption including the metabolised fractions, however, this was not possible for our swine 432 
study due to the high cost of handling radioactive waste. With the linear dose-response 433 
relationship using the parent compound (B[a]P) observed in both the two animal models, we 434 
think it is prudent to use AUC of the parental compound to represent absorption within each 435 
animal model and RB can be compared between the two models. 436 
 437 
The presence of a slightly faster peaking concentration of B[a]P in plasma is most likely due 438 
to the higher fundamental metabolic rate in the smaller animal (Kleiber 1947) and possibly 439 
has been influenced by the different food constituents dosed along with soil/sand. The lower 440 
B[a]P concentration in plasma in swine may either be due to a lower absorption including 441 
partitioning from gastrointestinal organ to blood or higher metabolic rate specific for 442 
biotransformation of the parent compound. Actually, partition from organ to blood has been 443 
reported to be half in humans compared to that in rats (Crowell et al. 2011), and this may 444 
probably apply to swine when compared with rat.  445 
Correlation between the RBrat and RBswine (RBrat = 0.26RBswine + 17.3, R2 = 0.70, p < 0.001) 446 
suggested bioavailability may be underestimated if RB derived from the rat model was used 447 
for soil guideline derivation directly. However, the reality is an interspecies difference 448 
uncertainty factor is already incorporated in the guideline derivation. The US EPA. (2011) set 449 
up a default adjusting factor of 10 for the deviation of an equivalent dose for human (RfDH) 450 
from an animal study while a body weight scaling method using bw3/4 which was 451 
recommended when extrapolating data from different animal models and a rounded 452 
uncertainty factor of 3 accounting for pharmacodynamics differences. The body weight 453 
scaling factor was approximately 3-fold from rat (0.35 kg) to swine (32 kg) and 1.2-fold from 454 
swine to human (70 kg). Our comparative study showed a good consistency in the RB in the 455 
aged soils between the two animal models and the difference between rat and swine was about 456 
4 which is close to the body weight scaling method. Further studies may be required to 457 
investigate the carcinogenic competency (pharmacodynamics) of contaminants for the 458 
reference material. A freshly spiked silica sand was used in both rat and swine. It is 459 
recommended in the future that analyses link the toxicity of this material to that used by Culp 460 
et al. (1998). 461 
 462 
It is difficult to remove the uncertainties in the interspecies extrapolation unless human 463 
epidemic data can be generated. However, our data from the rat and swine models supported 464 
the body weight scaling method which was recommended by the US EPA where uncertainty 465 
in the pharmacokinetic component is reduced. The difference in the carcinogenic competency 466 
between rat and swine will require a long-term carcinogenic analysis where carcinogenic 467 
endpoints can be determined. Alternatively, it would be advantageous if a conservative 468 
guideline for the plasma B[a]P assay can be recommended for screening exposure, just like 469 
the case of lead, where blood lead concentration was adopted.  470 
Conclusion 471 
 472 
Comparing RB of B[a]P between the rat and swine models in this study established a link 473 
between the two animal models for the first time. Although the results derived from the rat 474 
model were not as sensitive to the changes over ageing as well as to the influences of soil 475 
properties compared to that derived from the swine model, it accounts for about 70% of the 476 
variability in the swine study results. These findings have important implications for reducing 477 
uncertainties in the interspecies extrapolation from experiment animals to human with 478 
reference to human health risk assessment. Further research on the cancer competency of 479 
B[a]P for different animal models and the applicability for PAH mixtures is required. 480 
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